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Introduction
Essential thrombocythemia (ET) is a myeloprolifera-
tive disorder characterized by chronically abnormally 
high platelet count and risk of thrombotic and hemor-
rhagic events, which can complicate perioperative man-
agement of cardiovascular surgery. On the other hand, 
hypothermic circulatory arrest (HCA) is an effective brain 
protection technique, but its major cause for concern is 
hypothermia-induced coagulopathy. Few reports are avail-
able on cardiac surgery using HCA in ET patients. Here, we 
present the case of a patient with ET who underwent aor-
tic valve and ascending aorta replacement under HCA.
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We present the case of a 61-year-old patient with a history of essential thrombocythemia 
(ET) who was diagnosed as having aortic valve stenosis and dilatation of his ascending 
aorta. His aortic valve and ascending aorta were replaced under hypothermic circula-
tory arrest (HCA). No clear guideline exists for preoperative, perioperative, and post-
operative management of cardiac surgery using HCA for ET patients. After performing 
risk assessment, we prescribed preoperative aspirin therapy and postoperative care was 
planned as usual for cardiovascular surgery in our establishment. Unexpectedly, acti-
vated clotting time did not exceed 400 seconds, but the course of treatment was other-
wise uneventful.
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Case Report
A 61-year-old Japanese male with symptomatic 
moderate-to-severe stenosis of his bicuspid aortic valve, 
and with significant dilatation of his ascending aorta, 
was referred to us about 6 months after initial diagnosis. 
He suffered recurrent chest pain and dyspnea on exer-
tion. Echo-Doppler evaluation revealed his bicuspid aor-
tic valve with severe calcification and decreased mobility 
of the leaflets, but no regurgitation. The peak pressure 
gradient across the aortic valve was 66 mmHg, his aor-
tic valve area was 1.15 cm2 (indexed AVA 0.61 cm2/m2), 
with a peak trans-aortic flow velocity of 4.1 m/s. Preop-
erative computed tomography demonstrated a fusiform 
aneurysm of his ascending aorta with a maximum diam-
eter of 48 mm. The only notable anomaly in his previous 
medical history was essential ET, which was diagnosed 
by the absence of reactive conditions (blood loss, iron 
deficiency, infection, etc.) and other clonal disorders 
(myeloproliferative disease and myelodysplastic syn-
dromes). This diagnosis was made by a specialist in the 
Japanese Society of Hematology. The patient had no 
definitive history of thromboembolic events although 
his baseline platelet count had ranged between 640 × 
103/µL and 760 × 103/µL. Other laboratory results were 
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as follows: white blood cell count, 12900/µL; analysis of 
coagulation was normal (except for activated partial 
thromboplastin time at 42.5 seconds; von Willebrand 
factor antigen: 127%; von Willebrand factor activity 
76%; cold agglutinin titer test: 1/16). The platelet aggre-
gation test, with either adenosine diphosphate (ADP) or 
collagen, showed reduced area under the curve (Fig. 1). 
A bone marrow biopsy showed megakaryocytic hyper-
plasia with preserved maturation and no change in the 
erythrocyte and granulocyte series; neither fibrosis nor 
dysplastic change was observed. The janus kinase 2 
(JAK2) mutation was detected (Fig. 2), and the test result 
for expression of breakpoint cluster region/abelson 
(BCR/ABL) was negative (Fig. 3). He had started on a 
low-dose aspirin therapy (100 mg/day) for this condition 
6 months before presenting at our hospital, and it was 
continued preoperatively and postoperatively.
The operation was performed under general anesthe-
sia, and the sternum was opened. After heparin sodium 
300 IU per kg bodyweight had been given intrave-
nously, the activated coagulation time (ACT) increased 
from 139 seconds to 352 seconds, but because ACT 
did not exceed 400 seconds, additional heparin sodium 
5000 IU was added twice (for an eventual ACT of 
363 seconds). Cardiopulmonary bypass (CPB) was initi-
ated by ascending aorta blood delivery and superior and 
inferior vena cava blood removal. CPB was suspended at 
a tympanic temperature of 25°C, when the aorta was 
opened. The myocardium was protected by retrograde 
cardioplegia. Replacement of the ascending aorta was per-
formed using an open distal anastomosis technique under 
circulatory arrest only. After completion of the distal repair, 
the vascular prosthesis (J Graft SHIELD NEO, Japan Life-
line, Tokyo, Japan) was clamped, then antegrade systemic 
circulation was restarted through the side branch of the 
prosthesis, and rewarming was begun. After confirmation 
that the aortic valve was bicuspid, that valve was resected 
and replaced with a bioprosthetic valve (Carpentier- 
Edwards Perimount (CEP) Magna Ease, Edwards Life-
sciences, Irvine, CA, USA) in a supra-annular position. 
The proximal anastomosis was performed about 1 cm 
above the sinotubular junction. After that, coronary circu-
lation was restarted. No clots were seen in the circuit, and 
weaning from CPB was trouble-free. Protamine sulfate 
310 mg was administered intravenously to neutralize the 
heparin, and the ACT returned to 149 seconds. The CPB 
time was 103 minutes, the cross clamp time was 74 min-
utes, and the HCA time was 16 minutes (Fig. 4). Intraop-
erative blood transfusion was not required.
The patient was extubated 14 hours later, and he left 
intensive care unit on postoperative day 1. Aspirin 100 mg 
per day, and warfarin controlled from prothrombin time- 
international normalized ratio (PT-INR) 1.6 to 2.6, were 
started on postoperative day 1. Postoperative recovery 
was uneventful. He was discharged on postoperative 
day 17. Platelet counts during hospitalization were under 
700 × 103/µL. No thrombotic or bleeding episodes 
occurred through postoperative day 749.
Fig. 1  The platelet aggregation test, with either ADP or collagen, showed reduced area under the 
curve. ADP: adenosine diphosphate
Channel No CH. 1 CH. 2 CH. 3 CH. 4
Test reagent ADP ADP Coll Coll
Concentration 1.0 3.0 0.25 2.0
Unit
(a) (b)
uM uM ug/ml ug/ml
Maximum aggregation 8% 24% 4% 4%
Appearance time 0:12 0:32 0:06 0:04
3 min aggregation 6% 7% 2% 2%
5 min area 330 491 120 63
Slope 22° 74° 45° 35°
Lag Time ** **
Fig. 2  The JAK2 mutation was detected. JAK2: janus kinase 2
Mutation
Result Unit Reference valueItem name
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Discussion and Conclusion
We are unaware of any clear guideline for preopera-
tive, perioperative, and postoperative management of 
cardiac surgery for patients with ET. ET is classified into 
two groups according to risk of thrombosis: high risk 
(age ≥60 years, or history of thrombosis, or platelet count 
≥1500 × 103/µL) and low risk (age < 60 years, no history 
of thrombosis, and platelet count <1500 × 103/µL).1) 
ET may also be classified into three groups according to 
life expectancy: high risk (age ≥60 years and WBC count 
≥15000/µL), intermediate risk (age ≥60 years or white 
blood cell [WBC] count ≥15000/µL), and low risk (age 
< 60 years WBC count <1500 × 103/µL).2) The reference 
indicates that cytoreductive therapy is not needed in 
low-risk ET patients, while recommending the use of 
low-dose aspirin in the presence of vasomotor symptoms 
or general indications for aspirin use.3) Meanwhile, high-
risk ET patients should be treated with cytoreductive 
therapy and low-dose aspirin.4) We founds 12 published 
case reports describing patients with ET undergoing 
cardiovascular procedures requiring CPB.5–16) Of these 
12 patients, 3 patients reportedly suffered major compli-
cations postoperatively, and all three had preoperative 
platelet counts greater than 800 × 103/µL. These three 
patients were classified as “high risk” for thrombosis and 
“intermediate risk” for life expectancy, and baseline 
platelet counts had ranged between 640 × 103/µL and 
760 × 103/µL. Because of them, we treated this case with 
only aspirin in the preoperative period.
Because this case involved cardiac surgery with both 
CPB and HCA, some risk of adverse events in the hemo-
static and coagulation system had been expected. Few 
English-language reports have been published on car-
diac surgery using HCA in ET patients. Because this 
case had been categorized as high risk for thrombosis but 
intermediate risk for life expectancy, with platelet count 
Fig. 3  The test result for expression of BCR/ABL was negative. Mononuclear cell’s BCR/ABL was negative, and neutrophil cell’s 
BCR/ABL was also negative. BCR/ABL: breakpoint cluster region/abelson
Negative Positive
Number of measurements 200 0
Detection rate 100.0% 0.0%
Negative Positive
Number of measurements 200 0
Detection rate 100.0% 0.0%
BCR/ABL (b) – Neutrophil cellBCR/ABL(a) - Mononuclear cell
BCR/ABL - Mononuclear cell fusion signal BCR/ABL – Neutrophil cell fusion signal
Fig. 4  After aortic valve replacement (CEP Magna Ease 27 mm) 
and ascending aorta replacement (J Graft SHIELD NEO 
30 mm). CEP: Carpentier-Edwards Perimount
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stable at less than 800 × 103/µL, perioperative and post-
operative management was planned as usual for cardio-
vascular surgical cases in our hospital. Postoperatively, 
this case was treated with aspirin for oral antiplatelet 
therapy and warfarin as an oral anticoagulant. Warfarin 
was ended 3 months after surgery, and aspirin was con-
tinued. The postoperative course was smooth, the dura-
tion of hospitalization was 17 days, and no thrombotic or 
bleeding episodes have occurred through postoperative 
day 739.
After heparin administration at the start of CPB, the 
failure to extend ACT past the threshold of 400 seconds 
was unanticipated although such heparin resistance 
is not unprecedented.4) We decided to pursue opera-
tion with CPB if the ACT could be extended beyond 
350 seconds, so the patient was given 31000IU of hep-
arin sodium in total. The results were good, the reser-
voir did not need to be changed and no clots were seen 
during CPB. The operation was performed with no 
undue difficulty. This case happened to be a successful 
case, but accumulation of data from far more cases will 
be needed before conclusions can be drawn.
In conclusion, we performed aortic valve replacement 
with a bioprosthetic valve and ascending aorta replace-
ment using HCA in this patient with ET. As hoped, our 
standard surgical technique, with careful preoperative 
and postoperative management produced an uneventful 
result, but we suspect that treatment interventions based 
on thrombosis risk and life expectancy risk deserve fur-
ther consideration.
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